Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Novartis will eliminate 285 jobs across units in New Jersey. The terminations will take effect on January 28, 2023.
The FDA lifted its partial clinical hold on bluebird’s experimental sickle cell disease gene therapy for patients younger than 18.
Pfizer is rapidly scaling up its AI/ML efforts in a collaborative effort intended to get transformative medicines to patients faster.
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.
Madrigal’s NASH drug hits the mark in late-stage trial.
Q1 is the time when life science professionals are ramping up their job search efforts. If this applies to you, here are some tips to help you get a head start and prepare for your Q1 job search.
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
Astellas’ zolbetuximab hit the mark in a second late-stage trial in Claudin-18.2-positive gastric cancer.
Covalent biologic company Enlaza launches with $61M in seed financing.
Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
BioCryst Pharmaceuticals is discontinuing the development of its Factor D inhibitor BCX9930 in paroxysmal nocturnal hemoglobinuria due to competitive factors.
